<DOC>
	<DOC>NCT01764425</DOC>
	<brief_summary>Clinical trial to study the safety tolerability, pharmacokinetics, food effect and pharmacodynamics of a new compound P7435 in in healthy, overweight and/or obese subjects</brief_summary>
	<brief_title>Clinical Trial to Study the Safety Tolerability, Pharmacokinetics, Food Effect &amp; Pharmacodynamics of a New Compound P7435 in Healthy, Overweight and/or Obese Subjects</brief_title>
	<detailed_description>- A phase I, randomized, double-blind, placebo-controlled, dose escalating study of P7435 to determine the safety, tolerability, pharmacokinetics, food effect and pharmacodynamics of single and multiple ascending doses of P7435. - Subjects participating will be either healthy subjects or healthy overweight and/or obese subjects. In this study, overweight/obese are defined as subjects having a BMI of 23 kg/m2 and above. - The study will be conducted in 3 parts as follows: Part A will consist of the Single Ascending Dose (SAD) study, Part B will consist of the Multiple Ascending Dose (MAD) study and Part C will consist of the Food Effect study.</detailed_description>
	<mesh_term>Overweight</mesh_term>
	<criteria>Willingness and are able to provide a written informed consent to participate in the study. Healthy adult male subjects aged between 18 and 45 (both inclusive) years old BMI between 19 and 23 kg/m2. Overweight (BMI between 23 and 25kg/m2) and/or obese (BMI between 25 and 35 kg/m2) but otherwise healthy subjects in PartB . Healthy as determined by the investigator Smoking less than 10 cigarettes per day and able to refrain from smoking during confinement. Ability and willingness to abstain from alcohol, methylxanthinecontaining beverages or food (coffee, tea, coke, chocolate, "power drinks") and grapefruit juice to admission. Employees of the sponsor or clinical sites. Female subjects. No past or current serious diseases of any organ will be allowed. Exceptions may be nonmalignant skin diseases, childhood asthma and other conditions as per the Investigator's discretion and discussed with the Sponsor a priori. History of significant gastrointestinal disease or other significant diseases including cardiac, renal or liver impairment. History of sleep apnea, irregular sleep/wake cycle or working in night shifts. Acute disease state History of hypo/hyperthyroidism or repeated abnormal TSH values at screening or obesity of endocrine origin. History of alcoholism for more than 2 years Positive serology for human immunodeficiency virus (HIV1/2) antibodies, hepatitis B surface antigen (HBsAg), and/or hepatitis C virus (HCV) antibodies. Positive findings in urine drug screen / alcohol breath test. Participation in another clinical trial within 90 days of the first drug administration. Intake of more than 810 cups of coffee and/or tea per day and consumption of methyl xanthinecontaining beverages (tea, coffee, cola drinks, chocolate) within 48 hours prior to study. Donation of blood (i.e. 350 ml) within 90 days before Day 1 of the first treatment period.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>P7435</keyword>
	<keyword>Healthy,overweight and or obese subjects</keyword>
	<keyword>Single ascending dose</keyword>
	<keyword>Multiple ascending dose</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>